{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019162","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.708453+00:00","generated_at":"2026-06-15T09:16:09.203145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cogent Biosciences Q1 net loss widens to $38.6M; cash $220.3M, runway into 2025; AdvSM trial expands","bullets":["Cash and marketable securities $220.3M at March 31, 2023, down from $259.3M at Dec 31; funding expected into 2025.","Net loss of $38.6M for Q1 2023 vs $30.6M in Q1 2022; R&D expenses $36.0M (+41% YoY) driven by clinical trials.","Initiated Part 2 of Phase 2 APEX trial in Advanced Systemic Mastocytosis at 150 mg; enrollment target by end-2024.","FDA granted Orphan Drug Designation for bezuclastinib in mastocytosis (including SM); ~30,000 annual US diagnoses.","Upcoming data: PEAK GIST lead-in safety/efficacy at ASCO June 2023; SUMMIT NonAdvSM and APEX Part 1 data in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019162","json":"https://secwatch.observer/filing/0000950170-23-019162.json","markdown":"https://secwatch.observer/filing/0000950170-23-019162.md","text":"https://secwatch.observer/filing/0000950170-23-019162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/0000950170-23-019162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/cogt-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:16:09.203145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"110aec0a11211102d8e31075d988edd276dadd2b","claim":"Cogent Biosciences, Inc. reported the first quarter ended March 31, 2023 results: net income $38.6 million.","evidence_excerpt":"Net loss was $38.6 million for the first quarter of 2023 compared to a net loss of $30.6 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/0000950170-23-019162-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$38.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}